Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy.

ABSTRACT:

Background & objective

"Anti-angiogenetic drugs plus chemotherapy" (anti-angio-chemo) and "immune checkpoint inhibitors plus chemotherapy" (ICI-chemo) are superior to traditional chemotherapy in the first-line treatment of patients with advanced non-small-cell lung cancer (NSCLC). However, in the absence of a direct comparison of ICI-chemo with anti-angio-chemo, the superior one between them has not been decided, and the benefit of adding anti-angiogenetic agents to ICI-chemo remains controversial. This study aimed to investigate the role of antiangiogenic agents for advanced NSCLC in the era of immunotherapy.

Methods

Eligible randomized controlled trials (RCTs) comparing chemotherapy versus therapeutic regimens involving ICIs or anti-angiogenetic drugs were included. Outcom

SUBMITTER: Pang LL 

PROVIDER: S-EPMC9862794 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature